One popular option, Weight Loss by Hers, is a holistic program personalized for you. The program features four pillars of ...

Truist analyst Jailendra Singh raised the firm’s price target on Hims & Hers to $39 from $24 and keeps a Hold rating on the shares after ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

The pharma giant will now offer 7.5mg and 10mg dosages of Zepbound, as well as lower rates for its 2.5mg and 5mg vials.

The report suggests compounders may be using illegally imported APIs made in unregistered overseas facilities.

Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.

Eli Lilly ( LLY 2.31%) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...